Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers are scheduled to present new data from the extension phase of two clinical studies examining the long-term efficacy and safety of asfotase alfa in infants and juveniles with hypophosphatasia (HPP) at the joint meeting of the Pediatric Academic Societies (PAS) and the Asian Society for Pediatric Research, which takes place May 3-6, 2014 in Vancouver, B.C., Canada. The meeting will also feature the presentation of results from a retrospective natural history study of patients with perinatal and infantile HPP.
Help employers find you! Check out all the jobs and post your resume.
